CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood ...

Growing Demand for Cerus’ INTERCEPT® Pathogen Inactivation System for Plasma Drives Additional Investment in Microsize’s Particle Sizing Services. QUAKERTOWN, Pa.--(BUSINESS WIRE)--Microsize today ...

The Company is reiterating its full-year 2025 annual product revenue guidance range of $194 million to $200 million, which includes $12 million to $15 million for INTERCEPT Fibrinogen Complex (IFC).

Concord, Calif.-based Cerus announced today an agreement with the Biomedical Advanced Research and Development Authority, a segment of the U.S. Department of Heath and Human Services’ Office of the ...

Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive ...

Samsung Electronics forecasted strong artificial intelligence-driven demand for chips in the second half of this year, as it reported a more than 15-fold rise in its second-quarter operating profit.

Regulatory Approval Allows Company to Initiate Commercialization of the Illumination Device throughout the European Union CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (CERS) announced today ...